Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AM003 in advanced solid tumors
NCT06258330Phase 1Completed
- Sponsor
- Aummune
- Start
- Jun 2022
- Primary completion
- Jul 2024
- Modality
- RNA Aptamers, Small Molecules, DNA Aptamers
- Countries
- 1
01
Overview
Phase 1, open-label trial of AM003 in solid tumor (3 cohorts), sponsored by Aummune. Primary endpoints: Number of SAEs, TEAEs assessed by CTCAE v.5.0 at 28 days and Number of TEAEs meeting protocol defined DLT criteria at 28 days. Started Jun 2022; status: completed.
02
Drugs
AM003
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06258330.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06258330.